Psoriasis Trial, Recruiting NCT06029257 Sponsor: Almirall, S.A. Condition: Psoriasis
Back to Psoriasis

Psoriasis Trial, Recruiting

NCT06029257
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with psoriasis that significantly affects the genital area (with a severity score of 3 or higher on a standard medical scale).
  • Your doctor has decided you need a biologic treatment (a type of medication given by injection), and the specific medication called tildrakizumab has been chosen as your treatment.
  • You are between 18 and 99 years old.
  • You are willing to sign a consent form agreeing to take part in the study.
  • You have plaque psoriasis affecting at least 1% of your body surface area in an area other than the genitals.
  • You are willing and able to complete questionnaires as part of the study.

Who may not be able to join:

  • You are unwilling or unable to follow the study requirements, or your doctor does not think you should participate.
  • You have taken part in any experimental treatment in the past 3 months before the start of the study.
  • You have any health condition that means you cannot safely take tildrakizumab, including a known allergy or bad reaction to it in the past (confirm with trial site).
  • You are an employee of, or otherwise dependent on, the team running the study.
  • You have previously been treated with tildrakizumab.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +43 0 15953960

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Almirall, S.A.
Registry
ClinicalTrials.gov
Start date
14 November 2023
Est. completion
1 March 2026

Where this trial is recruiting

🇦🇹 Austria

Primary endpoints

Percentage of Participants Achieving a Static Physician's Global Assessment of Genitalia (sPGA-G) Score of "Clear" (0) or "Almost Clear" (1); Change From Baseline in Modified Genital Psoriasis Area and Severity Index (mGPASI) Score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov